IVIG To SCIG Transition denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies the IVIG-to-SCIG Transition as Not FDA-Approved

Blue Cross Blue Shield may issue a not-FDA-approved denial when the specific SCIG product ordered is not recognized in the plan's internal coverage database as FDA-approved for the patient's diagnosis, or when the denial is generated by an automated system that does not match the submitted diagnosis code to the product's approved labeling. In reality, multiple SCIG products hold FDA approval for immunodeficiency and other immunoglobulin-replacement indications. This type of denial is typically among the most straightforward to overturn — the FDA label is definitive, and presenting it directly rebuts the denial's factual premise.

## Why This Denial Is Appealable

A not-FDA-approved denial rests on a factual claim that can be disproved with documentation. Under ACA §2719, external independent reviewers assess coverage decisions against current medical and regulatory standards; presenting the FDA label directly undermines the insurer's position. Under ERISA §503, you are entitled to a full-and-fair review that considers all submitted evidence. File your internal appeal within the deadline on your EOB (typically 180 days), and if denied, request external review within the standard 4-month window. Expedited review is available for urgent situations.

## The Concrete Appeal Process

1. Obtain the current FDA-approved prescribing information (package insert) for the exact SCIG product ordered — this is publicly available from the FDA's Drugs@FDA database. 2. Confirm the listed indication(s) match the patient's documented diagnosis. 3. Submit the internal appeal with the FDA label, a cover letter citing the relevant approved indication, and the prescriber's diagnosis confirmation. 4. If denied internally, carry the same documentation to external review.

## Documentation to Gather

• FDA prescribing label: The full, current package insert for the prescribed SCIG product, with the approved indication highlighted.
• Diagnosis documentation: Specialist chart notes and any prior diagnostic workup that establish the diagnosis matching the FDA-approved indication.
• Prescriber letter: Confirms the ordered product is FDA-approved for the patient's condition and explains the clinical rationale for the IVIG-to-SCIG transition.
• IVIG treatment history: Demonstrates established prior use of immunoglobulin therapy, supporting continuity of care.
• Denial letter and policy: The BCBS denial with the cited coverage policy, so the appeal can address the exact language used.

## Criteria-Mapping Structure

Pull the BCBS coverage policy cited in the denial alongside the FDA label. Address each point of the denial directly:

| Denial Claim / Policy Criterion | Rebuttal Evidence | |---|---| | "Product not FDA-approved" | [FDA label — product name, approval date, listed indication] | | [Any additional policy criterion] | [Matching chart fact or label reference] |

Keeping the rebuttal factual and document-anchored — not argumentative — is most effective. The FDA label speaks for itself.